| Autor: |
T J, Haller, X L, Yin, T J, O'Byrne, E J, Moore, D J, Ma, K P, Price, S H, Patel, M L, Hinni, M A, Neben-Wittich, L A, McGee, D L, Price, J R, Janus, J K, Kasperbauer, T H, Nagel, D M, Routman, S C, Lester, J C M, Rwigema, A V, Chintakuntlawar, P S, Savvides, J J, Garcia, R L, Foote, K M, Van Abel |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Oral Oncology. 137:106248 |
| ISSN: |
1368-8375 |
| Popis: |
Dose de-escalation of adjuvant therapy (DART) in patients with HPV(+)OPSCC was investigated in two prospective Phase II and III clinical trials (MC1273 and MC1675). We report the 30-day morbidity and mortality associated with primary TORS resection in patients enrolled in these trials.Patients with HPV(+)OPSCC, who underwent TORS resection between 2013 and 2020 were considered in this analysis. The severity of postoperative transoral bleeding was graded using both the Hinni Grade (HG) transoral surgery bleeding scale and the Common Terminology for Adverse Events (CTCAE) v5.0. Post-surgical complications within 30 days of surgery, as well as rates of tracheostomy, PEG and nasogastric tube placement.219 patients were included. A total of 7 (3.2 %) patients had a tracheostomy placed at the time of surgery, and all were decannulated within 26 days (median: 5, range: 2-26). There were 33 (15.1 %) returns to the emergency department (ED) with 10 (4.6 %) patients requiring readmission. Using the HG scale, 10 (4.6 %) patients experienced ≥ Grade 3 bleeding with no Grade 5 or 6 bleeds. In contrast, using the CTCAE scale, 15 patients (6.8 %) experienced ≥ Grade 3 bleeding with no Grade 5 bleeds. There was one post-operative death in a patient withdrawn from the trial, and no deaths related to hemorrhage.TORS for HPV(+)OPSCC in carefully selected patients at a high volume center was associated with low morbidity and mortality. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect